NCT05337319

Brief Summary

The study will estimate the current status of care for participants with coronary artery disease

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
32mo left

Started Jan 2022

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Jan 2022Dec 2028

Study Start

First participant enrolled

January 17, 2022

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 13, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 20, 2022

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2028

Last Updated

May 26, 2022

Status Verified

May 1, 2022

Enrollment Period

6 years

First QC Date

April 13, 2022

Last Update Submit

May 20, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • The overall composite of 10 performance measures for CAD care

    Performance measures for CAD care including: Proportion of patients received fibrinolytic therapy within 30 mins (STEMI) Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI) Proportion of patients received reperfusion therapy (STEMI, high or moderate risk NSTE-ACS) Proportion of patients with aspirin prescribed at discharge Proportion of patients with P2Y12 inhibitors prescribed at discharge Proportion of patients with beta-blocker prescribed at discharge Proportion of patients with statin prescribed at discharge Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge Proportion of patients received evaluation of left ventricular systolic function Proportion of patients with a diagnosed non-obstructive coronary artery disease at discharge

    Duration of hospital stay, an expected average of 1 week

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Hospitalized patients with coronary artery disease

You may qualify if:

  • Hospitalized patients with discharge diagnosis as coronary artery disease (including atherosclerosis or non-athrosclerosis)

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Anzhen Hospital

Beijing, China

RECRUITING

MeSH Terms

Conditions

Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Study Officials

  • Shaoping Nie, MD, PhD

    Beijing Anzhen Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shaoping Nie, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 13, 2022

First Posted

April 20, 2022

Study Start

January 17, 2022

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2028

Last Updated

May 26, 2022

Record last verified: 2022-05

Locations